Cancer· 2026Q1· Review
Clinical management of clonal hematopoiesis
- 0citations
- Q1SCImago
- 2026year
Short summary
Clonal hematopoiesis, an age-related premalignant condition detected in peripheral blood, is associated with increased risk of hematologic malignancies and nonmalignant conditions like cardiovascular disease.
AI-generated from the title and abstract; the full text is not read.
Key points
- Clonal hematopoiesis is an age-related premalignant condition involving somatic mutations in hematopoietic clones.
- It is increasingly detected via peripheral blood, even in healthy individuals.
- Associated mutations increase the risk of hematologic malignancies (e.g., MDS, AML) and nonmalignant conditions (e.g., cardiovascular disease).
- Clinical management involves individualized approaches to diagnosis, risk stratification, surveillance, and comorbidity mitigation due to a lack of consensus guidelines and approved therapies.
AI-generated from the title and abstract; the full text is not read.
Abstract
ABSTRACT Clonal hematopoiesis, particularly clonal hematopoiesis of indeterminate potential and clonal cytopenia of undetermined significance, is an age‐related premalignant condition characterized by the expansion of hematopoietic clones carrying somatic mutations. Because of the accessibility of peripheral blood, it has been increasingly detected, even in otherwise healthy individuals. Although often asymptomatic, specific clonal hematopoiesis–associated mutations and clonal features are associated with an increased risk of progression to hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia. Beyond malignant transformation, clonal hematopoiesis also has systemic implications and has been linked to a variety of nonmalignant conditions, such as cardiovascular and inflammatory disease. In this review, we focus on the clinical management of clonal hematopoiesis, including approaches to diagnosis, tools for risk stratification, and strategies for surveillance and comorbidity mitigation. In the absence of consensus guidelines and approved therapies, management remains individualized, underscoring the need for continued research and clinical trials to guide evidence‐based care and improve patient outcomes.
The authors' abstract, as published at the source. Cancer, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Hematology
HematologyMedicine